• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

Office of Drug Evaluation III (ODEIII) Divisions and Programs



The Office of Drug Evaluation III (ODEIII) is responsible for making safe and effective drugs multiple therapeutic areas available to the U.S. public. ODEIII has the following components:


Immediate Office

Director: Julie Beitz, M.D.
Deputy Director: Amy Egan, M.D.

Associate Director For Regulatory Affairs: Maria R. Walsh, R.N., M.S.
Regulatory Scientist: Vacant
Program Support Specialist: Diane Thomas


Return to the Office of Drug Evaluation III (ODEIII) page